Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study

María Angeles Vaz Salgado*1, Julie Earl1, Victor Rodriguez Berrocal2, Freddy Salge Arrieta2, Ana Gomez1, Juan Manuel Sepulveda-Sanchez1, Ángel Perez-Nuñez1, Elena Corral de la Fuente1, Daniel Lourido5, María Villamayor1, Hector Pian6, Alfonso Muriel7, Elisabetta Rossi8,9, Rita Zamarchi9, Alfredo Carrato1, Luis Ley2

1 Medical Oncology Department. Ramón y Cajal Hospital. IRYCIS, CIBERONC, Madrid, 28034, Spain
2 Neurosurgery Department. Ramón y Cajal Hospital, Madrid, 28034, Spain
3 Medical Oncology Department. 12 de Octubre Hospital. Instituto de Investigación I+12, Madrid, 28041, Spain
4 Neurosurgery Department. 12 de Octubre Hospital, Madrid, 28034, Spain
5 Radiology Department. Ramón y Cajal Hospital, Madrid, 28034, Spain
6 Pathology Department, Ramón y Cajal Hospital, Madrid, 28034, Spain
7 Clinical Biostatistic Unit, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERESP. Nursing Department Universidad de Alcalá Madrid, 28034, Spain
8 Department of Surgery, Oncology & Gastroenterology, University of Padova, Padua, 35124, Italy
9 Veneto Institute of Oncology IOV – IRCCS, Padua, 35128, Italy
*Author for correspondence: Tel.: +34 913 368 215; mariaangeles.vaz@salud.madrid.org

Aim: Glioblastoma (GB) is an aggressive tumor type and the detection of circulating endothelial cells (CECs) in peripheral blood has been related to angiogenesis. Materials & methods: A prospective single-center pilot study of CEC detection at diagnosis in 22 patients with GB was performed, using the US FDA-approved CellSearch system. Results: A CEC cutoff value was estimated using a receiver operating curve (ROC) and patients were classified into two groups: <40 CEC/4ml blood and >40 CEC/4 ml blood. Median overall survival was 25.33 months for group 1 and 8.23 months for group 2 cases (p = 0.02). There was no correlation between CEC and PWI (perfusion-weighted imaging) RM. Conclusion: CEC detection has a prognostic value in GB cases at diagnosis.

Plain language summary: Glioblastoma is an aggressive tumor type with a general poor prognosis. Endothelial cell detection in blood samples has been previously described as a marker of outcome in many tumor types. A US FDA-approved device, CellSearch, was used for CEC detection. The patients were split into two groups according to a cutoff value with the highest sensitivity and specificity, group 1 <40 and group 2 >40 CEC/4 ml blood. Patients with >40 CEC at diagnosis had a poorer overall survival; 25.33 months for group 1 and 8.23 months group 2 cases, which was statistically significant.

First draft submitted: 8 February 2021; Accepted for publication: 23 March 2022; Published online: 24 May 2022

Keywords: biomarker • circulating endothelial cells (CECs) • glioblastoma • perfusion MRI

Glioblastoma (GB) is a highly aggressive tumor, with a median survival of approximately 15 months in spite of treatment with surgery, radiotherapy and temozolomide. The current standard of care is surgery, radiotherapy and concomitant temozolomide followed by adjuvant cycles of temozolomide for at least 6 months [1]. GB is a very vascularized tumor and prognosis is related to this high vascularity. In addition, there is a need for minimally invasive biomarkers to monitor disease evolution during the treatment of GB [2,3]. Angiogenesis in the primary tumor can lead to vascular damage and shedding of endothelial cells into the blood stream. Circulating endothelial cells (CEC) are increasingly considered with interest as predictive biomarkers, as diverse stimuli facilitate cell migration from the bone to complement local angiogenesis [4].

CEC are endothelial cells that are present in the peripheral circulation and include endothelial progenitor cells (CEPs) and mature endothelial cells shed from vessels walls and cells with an endothelial function from cancerous...
Table 1. Patient characteristics.

| Characteristics        | Patients (n = 22) |
|------------------------|-------------------|
| Age, years (average)   | 63                |
| Median age (range)     | 42–81             |
| Sex                    |                   |
| Male                   | 63.6%             |
| Female                 | 36.4%             |
| ECOG (diagnosis)       |                   |
| 0                      | 27.3%             |
| 1                      | 68.2%             |
| ECOG post-surgery      |                   |
| 0                      | 22.7%             |
| 1                      | 72.7%             |
| 3                      | 4.5%              |
| Location               |                   |
| 1 – frontal            | 9 (41%)           |
| 2 – temporal           | 9 (41%)           |
| 3 – parietal           | 2 (10%)           |
| 4 – occipital          | 1 (4%)            |
| 5 – others             | 1 (4%)            |
| Extent of surgery      |                   |
| Biopsy                 | 18%               |
| Partial and subtotal resection | 32%             |
| Complete resection     | 50%               |

cells [5]. The mechanism of CEC shedding is not fully understood but is thought to be a consequence of physical damage to blood vessels, reduced adhesion and binding of cells with the basement membrane [6]. Therefore, CEC have been established as markers of endothelial damage or dysfunction and response to anti-angiogenic agents in various tumor types including breast, lung, colorectal and renal cancer [7,8,9,10]. CEC are rarely found in healthy individuals are usually found in individuals with disease such as COVID-19, blood vessel damage and cancer [6,8]. Furthermore, a recent study has shown that the ratio of viable: apoptotic CEC is an indicator of COVID-19 severity [9,10].

In cancer patients, the CEC number correlates with tumor progression and constitutes a promising tool to monitor disease activity, with the potential for the assessment of prognosis and response to treatment. In breast and lung cancer, an association has been observed between elevated CEC and longer progression free survival [8,11]. Previous reports established a correlation between CEP levels and tumor grade and prognosis in glioma patients [12,13].

Magnetic resonance imaging (MRI) is the gold standard imaging diagnosis for GB. Perfusion-weighted MRI (PWI) is a technique for the quantification of cerebral blood flow and volume (CBV). GB have been demonstrated to have regions of significantly elevated rCBV, consistent with their marked vascular proliferation [14].

This pilot study aimed to evaluate the potential prognostic value of CEC in patients with newly diagnosed GB in terms of survival. Levels of CEC, CEP, rCBV were determined in a cohort of patients with GB. These blood and RM-imaging biomarkers were hypothesized to be associated with a poorer prognosis.

Materials & methods
Patient selection
A prospective study was performed of patients with a newly diagnosed glioblastoma who received standard treatment at the Ramón y Cajal University Hospital in Madrid, Spain. The inclusion criteria were patients over 18 years of age, with a diagnosis of GB confirmed by histopathology. The patients were included between 2014 and 2016. Patients’ characteristics are shown in Table 1. All patients with a suspected glioblastoma and those willing to participate in this study were considered, therefore the sample can be considered representative of a larger population. At the time of the study inclusion, the WHO classification of 2016 was not in clinical use.
The patients received standard treatment based on radiotherapy and temozolomide as defined by the Stupp regimen. Some patients did not receive telozolomide as they were fragile and aged patients. After surgery, they received radiotherapy plus concomitant temozolomide followed by adjuvant temozolomide. Patients were assessed by magnetic resonance imaging (MRI). At progression, some patients were amenable for second-line treatment. Progression-free survival (PFS) was defined as the time from the initial histological GB diagnosis to time of disease recurrence or progression, based on imaging. Overall survival (OS) was defined as the time from the initial histological diagnosis to death. The clinical data were obtained from the hospital medical records. As this study was as an exploratory analysis, the sample size was determined by the number of patients diagnosed during this period of time and those that chose to participate in the study.

**CEC detection**

Peripheral blood samples were obtained at the time of diagnosis of glioblastoma. Endothelial cells were measured by the US FDA-approved CellSearch Assay® in 4 ml of whole blood as CD146+, CD105+ CD45-DAPI+. A total of 22 patients with glioblastoma were analyzed.

**MRI of glioblastoma**

The specific MRI protocols differed slightly between patients, however, they usually included T1-weighted pre- and post-contrast agent administration, fluid-attenuated inversion recovery, diffusion-weighted and T2-weighted scans. Dynamic susceptibility weighted was used for PWI, whereby dynamic MRIs were acquired after a bolus of contrast agent was administered intravenously. PWI was not performed in all patients as part of a standard brain tumor MRI protocol. For the quantification of the perfusion parameters, a ROI (region of interest) was drawn manually over the enhancing portions of the tumor, selecting visually those areas including the highest relative blood volume. Then the relative blood volume was calculated comparing the data obtained with the contralateral normal appearing white matter.

**Statistical analysis**

Statistical analysis was performed using the SPSS and R software. ROC curves (receiver operating curve) were used to estimate the cutoff value for CEC detection, and the patients were classified into two groups depending on the average number of CEC for subsequent analysis: group 1 had an average CEC count below 40 and group 2 had an average CEC count of 40 or above. OS and PFS were analyzed by the Kaplan–Meier method and survival curves of the subgroups were compared using the log-rank test. A Spearman test was performed to determine the correlation between CEC and rCBV parameters in MRI and the Mann–Whitney test to compare CEC count before and after surgery/radiotherapy.

**Results**

**Patient characteristics**

Twenty-two patients were included between 2014 and 2016. All patients had histologically confirmed glioblastoma. There were 14 males and 8 females and the average age was 63 years (range: 42–81 years). ECOG was 0–1 in 95% of cases. A complete resection was achieved in 50% of cases, partial or subtotal resection in 31.8% and biopsy in 18%. The extension of the resection was defined according to the opinion of the surgeon. All patients received radiotherapy and 3/22 (13.6%) did not receive concurrent temozolomide. 9/22 (41%) patients were treated with adjuvant temozolomide for six or more cycles.

**Circulating endothelial cell detection**

Determination of CEC was performed prior to the surgical procedure in 26 patients, 22 were high grade, recently diagnosed with glioblastoma. The average number of CEC was 59.3 cells/ml (range: 0–954) and 32% (7/22) patients were negative for CEC. The median number of CEC was 5 cell/4 ml. The sample cohort was divided into two groups according to the CEC count at diagnosis. The cutoff was calculated using the receiver operating curve (ROC) and the value with the highest sensitivity and specificity was selected. In this cohort, the cutoff value was 40 CEC/4 ml blood, HR 6.69 (IC: 1.72–25.92). Patients were classified into two groups: group 1 had a CEC count of ≤40 cells/ml and group 2 had a CEC count >40. A total of 17 patients (77.2%) were in group 1 and 5 patients (22.7%) were in group 2.
OS and adjuvant temozolomide

![Graph showing overall survival and circulating endothelial cells. The median overall survival was 17.4 months for patients in group 1 and 8.12 months for patients in group 2 (p < 0.001). n = 10, group 1; n = 5, group 2. OS: Overall survival.]

**CEC count & prognosis**

The median overall survival of the entire cohort was 11.8 months (range: 3.33–20.32) and was significantly associated with CEC count at diagnosis; 25.33 months (IC 95%: 8.65–42.0093) for patients in group 1 (<40 CEC) and 8.23 months for patients in group 2 (>40 CEC; IC 95%: 4.44–12.0; p = 0.02, Figure 1). Furthermore, the median progression free survival was higher in group 1, 8.94 months (IC 95%: 5.1–12.69) versus 3.95 months (IC 95%: 2.91–4.98) for group 2, but did not reach statistical significance (p = 0.097, Figure 2). This may be due to the limited size of the patient cohort. CEC count at diagnosis and after surgery and radiotherapy was available for five patients, there was an increase in the mean CEC count after surgery and radiotherapy (18 at diagnosis vs 19.4 after surgery and radiotherapy), although the difference did not reach statistical significance (Figure 3).

Median overall survival was significantly associated with the extent of surgery; 25.33 months (IC 95%: 5.54–45.12) for complete and subtotal resection and 8.23 months (IC 95%: 0.0–17.75) for partial resection or biopsy only (IC; p = 0.014) (Figure 4). However, this was not related to CEC count as an equal number of patients (8) from group 1 and group 2 were in the complete/subtotal and partial resection/biopsy group. Median overall was significantly associated with treatment with adjuvant temozolomide; 6.936 months (IC 95%: 0.744–13.12) for no adjuvant temozolomide or 17.42 months (IC 95%: 6.79–28.05) for adjuvant temozolomide, p ≤ 0.001 (Figure 5). Four patients who were initially considered for the study but whose pathological report did not confirm a glioblastoma were analyzed for CEC. The results were as follows: an oligoastrocytoma with 31 CEC, a low-grade astrocytoma with 4 CEC, an oligodendroglioma with 1 CEC and a recurrent glioblastoma with 4 CEC. One patient had CEC determinations at different stages of the tumor treatment. The patient started with 3 CEC prior to surgery. At the time of finishing radiotherapy there were 31 CEC and they then started temozolomide for 6 cycles and progressed. At this time, there were 1329 CEC and they started bevacizumab. After 9 months, they progressed and at this point the CEC count was 177.

**CEC count & MRI parameters**

A Spearman test was performed to determine a possible correlation between CEC and rCBV in the MRI. Spearman’s rho was 0.4563 (p = 0.1584). The preoperative CEC were not found to correlate significantly with the tumor rCBV.
Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study

Research Article

**Figure 2.** Progression-free survival and circulating endothelial cells. The median progression free survival was 8.94 months for group 1 and 3.95 months for group 2 (p = 0.097). n = 17, group 1; n = 5, group 2. CEC: circulating endothelial cell.

**Discussion**

CEC represent an attractive conceptual biomarker. Our results demonstrate that CEC can be detected in recently diagnosed glioblastoma patients. We found that the preoperative CEC counts in GB patients were significantly associated with a poorer OS and PFS. This may be related to the increased angiogenic process and its prognostic implications. These results suggest that there may be increased shedding of endothelial cells into the circulation from abnormal blood vessels in cases with the worst prognosis. Some studies have found an association between circulating markers and clinical outcome and showed that CEC pretreatment was associated with OS [15]. However, other studies in other tumor types have shown conflicting results with regard to the association between baseline CEC count and clinical outcome [16,17]. Preoperative CEC number in GB patients have been found to be significantly higher than the CEC number in human controls and it has also been determined that CEC levels decrease significantly in the postoperative period, although these studies did not find any correlation with PFS or OS [18]. In our study, there was an increase in CEC count after surgery and radiotherapy, which may be related to the vascular damage that occurs during targeted treated and has been previously reported [19]. However, other studies have shown a decrease in CEC levels after treatment with RT and concomitant temozolomid in Glioblastoma patients.
Overall survival and extent of surgery

Figure 4. Overall survival and extent of surgery. Median overall survival depending on the extent of surgery was 25.33 months (IC 95%: 5.54–45.12) for complete and subtotal resection and 8.23 months (IC 95%: 0.0–17.75) for partial resection or biopsy only (IC), p = 0.014. n = 16, complete/subtotal resection; n = 6, partial resection/biopsy.

OS and adjuvant temozolomide

Figure 5. Overall survival and adjuvant temozolomide. Median overall survival depending on treatment with adjuvant temozolomide was 6.936 months for no adjuvant temozolomide or 17.42 months for adjuvant temozolomide (p ≤ 0.001). n = 6, only radiotherapy; n = 15, adjuvant temozolomide. OS: Overall survival.

(refer). These differences may be due to the blood sampling time after treatment due to short- and long-term effects on CEC count [15].

An association between positive outcomes and number of CEC has been found in patients with cancer receiving antiangiogenic drugs, but nevertheless, this association has not been found by others [20,21,22,23,24,25]. For example, a decrease in CEC number and low baseline count have previously been correlated with a positive response to
bevacizumab [21,22]. However, there was no correlation between CEC level and PFS or OS in a trial of bevacizumab with sorafenib [23]. Other factors may also influence CEC numbers, such as dexamethasone (induction of endothelial inflammation) [24], contrast agents used in MRI scans (influences cell homing to the liver) [25] and epilepsy [26], which may lead to an increase in VEGF levels and affect the CEC number [27]. However, due to the limited size of the patient cohort, these factors and the effect of anti-angiogenic therapy on CEC count could not be accurately assessed in this study.

In this study, we verified the number of CEC after exposure to bevacizumab in one patient. The CEC count was 1329 when he started bevacizumab. After 9 months the patient progressed and at this point the CEC count was 177. In this case, bevacizumab seems to have some effect on peripheral CEC. In this study, the preoperative CEC were not found to correlate significantly with the PWI. Although the highest tumor vascularity detected by rCVB parameter could be expected to correlate with CEC, and other authors have found a correlation [18]. One possible explanation is the low number of patients analyzed that may limit the statistical analysis.

There are several limitations of the study that must be highlighted. First, the sample size is an important limiting factor due to the low frequency of this tumor type. Furthermore, CEC were detected in patients with other tumor types that were initially included in the study due to a suspicion of glioblastoma. This included, an oligoastrocytoma with 31 CEC, a low-grade astrocytoma with 4 CEC, an oligodendroglioma with 1 CEC and a recurrent glioblastoma with 4 CEC. This confirms that CEC are be present in other pathologic entities and are not specific to GB. Another limitation is that there have been a variety of immunophenotypic definitions for CEC and CEP that may contribute to the conflicting results in the literature. Searching for CTCs in the blood of patients with GB is difficult, given that reliable tumor-specific cell surface markers have yet to be established. As the CellSearch Assay® was used in this study, the CEC phenotype was strictly classified as CD146+, CD105+ CD45- and DAPI+, in accordance with the US FDA approval. However, other definitions of CEC have included CD45-/CD31bright/CD34+; CD45-/CD34+/CD146+ [4] and CD45-/AE5-/CD146+ [28]. Other studies in glioblastoma have used CEC definition as CD45-/CD31+ cells while CEP were defined as CD31+/CD133+ [18]. Others have defined CEC as CD34+/CD146+ CD45- and DRAQ5+ [29] or as CD45+/CD34+/CD133+ [30]. In spite of the limitations, this study provides preliminary data of the usefulness of CEC detection to predict prognosis in GB and highlights their potential use as a treatment response marker.

Conclusion
CEC count at diagnosis is a potential prognostic marker in glioblastoma patients.

Summary points
- Circulating endothelial cells (CEC) determination at diagnosis have a prognostic vale in glioblastoma patients.
- An average CEC count higher than 40 CEC/4 ml blood at diagnosis correlates with a poorer overall survival.
- An average CEC count higher than 40 CEC/4 ml blood at diagnosis correlates with a shorter progression free survival.
- There is no correlation between CEC count and PWI (perfusion-weighted imaging) RM.
- Patients that undergo a complete and subtotal resection have a better overall survival compared with those that undergo a partial resection.
- Adjuvant with temozolomide improves overall survival.

Author contributions
Conception: MA Vaz Salgado and L Ley. Interpretation or analysis of data: all authors. Preparation of the manuscript: MA Vaz Salgado, JM Sepulveda-Sanchez, J Earl and L Ley. Revision for important intellectual content: all authors. Supervision: MA Vaz Salgado and L Ley.

Financial & competing interests disclosure
The study was supported by Grupo Español de Investigación en Neurooncologia (GEINO). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.
Research Article Salgado, Earl, Rodriguez Berrocal et al.

Ethical conduct of research
The authors state that they have obtained appropriate approval of the ethics review board of the Ramón y Cajal University Hospital and have followed the principles outlined in the Declaration of Helsinki for research involving human subjects, informed consent has been obtained from the participants involved.

Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.future-science.com/doi/suppl/10.2144/fsoa-2022-0008

Open access
CC-BY: This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References
Papers of special note have been highlighted as: ● of interest; ●● of considerable interest
1. Stupp R, Mason W, van den Bent M et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005).
2. Kargiotis O, Ra J, Kyrtsis A. Mechanisms of angiogenesis in gliomas. J. Neurooncol. 78(3), 281–293 (2006).
3. Leon S, Folkert R, Black P. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77(2), 362–372 (1996).
4. Goon P, Lip G, Stonelake P, Blann A. Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia 11(8), 771–779 (2009).
5. Ricci-Vitiani L, Pallini R, Biffoni M et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468(7325), 824–830 (2010).
6. Goon P, Lip G, Boos C, Stonelake P, Blann A. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8(2), 79–88 (2006).
7. Bidard F, Mathiot C, Degeorges A et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 21(9), 1765–1771 (2010).
8. Mancuso P, Colleoni M, Calleri A et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108(2), 452–459 (2006).
9. Mancuso P, Gidaro A, Gregato G et al. Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases. J. Thromb. Haemost. 18(10), 2744–2750 (2020).
10. Zhang X, Jiang M, Yang J. Potential value of circulating endothelial cells for the diagnosis and treatment of COVID-19. Int. J. Infect. Dis. 107, 232–233 (2021).
11. Erdbruegger U, Dhaygude A, Haubitz M, Woywodt A. Circulating endothelial cells: markers and mediators of vascular damage. Curr. Stem Cell Res. Ther. 5(4), 294–302 (2010).
12. Greenfield J, Jin D, Young L et al. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurourosurgery 64(5), 819–826 (2009).

●● Describes surrogate markers of angiogenesis in glioblastoma, which applies to CECs (circulating endothelial cells) studied in our article.
13. Rafat N, Beck GCh, Schulte J, Tueutensberg J, Vajkoczy P. Circulating endothelial progenitor cells in malignant gliomas. J. Neurosurg. 112(1), 43–49 (2010).

●● Describes CEC detection in glioblastoma as a predictive marker.
14. Catalaa I, Henry R, Dillon W et al. Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. NMR Biomed. 19(4), 463–475 (2006).

● Describes other clinical markers in glioblastoma that were also studied in our article.
15. Reynés G, Vila V, Fleitas T et al. Circulating endothelial cells and procoagulant microparticles in patients with glioblastoma: prognostic value. PLoS ONE 8(7), e69034 (2013).

●● Describes CEC detection in glioblastoma as a predictive marker.
16. Beerepoot L, Mehra N, Vermaat J, Zonnenberg B, Gębink M, Voesen E. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann. Oncol. 15(1), 139–145 (2004).
17. Kawaishi M, Fujwara Y, Fukui T et al. Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J. Thorac. Oncol. 4(2), 208–213 (2009).
18. Bennett I, Guo H, Kountouri N et al. Prooperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme. J. Clin. Neurosci. 22(11), 1802–1808 (2015).

- Describes other clinical markers in glioblastoma that were also studied in our article.

19. Yang Y, Wang Z, Liu H, Zhou Y. Circulating endothelial cells in surgical patients. Cor Vasa. 34(4), 359–364 (1992).

- Describes CEC detection as a marker in surgery patients, although not in the context of glioblastoma is marker studied in our article.

20. Calleri A, Bono A, Bagnardi V et al. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin. Cancer Res. 15(24), 7652–7657 (2009).

21. Willett C, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10(2), 145–147 (2004).

22. Ronzoni M, Manzoni M, Mariucci S et al. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann. Oncol. 21(12), 2382–2389 (2010).

23. Batchelor T, Sorensen A, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1), 83–95 (2007).

24. Ding Y, Gao Z, Jacobson K, Suffredini A. Dexamethasone enhances ATP-induced inflammatory responses in endothelial cells. J. Pharmacol. Exp. Ther. 335(3), 693–702 (2010).

25. Soenen S, De Meyer S, Dresselaers T et al. MRI assessment of blood outgrowth endothelial cell homing using cationic magnetoliposomes. Biomaterials 32(17), 4140–4150 (2011).

26. Armstrong T, Grant R, Gilbert M, Lee J, Norden A. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. Neurol. Oncol. 18(6), 779–789 (2016).

27. Vezzani A. VEGF and seizures: cross-talk between endothelial and neuronal environments. Epilepsy Curr. 5(2), 72–74 (2005).

28. Cugno M, Borghi M, Lonati L et al. Patients with antiphospholipid syndrome display endothelial perturbation. J. Autoimmun. 34(2), 105–110 (2010).

29. Beije N, Kraan J, Taal W et al. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. Br. J. Cancer 113(2), 226–231 (2015).

30. Alexiou G, Vartholomatos G, Karamoutsios A, Baristatou A, Kyritsis A, Voulgaris S. Circulating progenitor cells: a comparison of patients with glioblastoma or meningioma. Acta Neurol. Belg. 113(1), 7–11 (2013).